Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Business & Industry
- Selumetinib granted orphan designation in Europe for neurofibromatosis type 1
- Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce new partnership to develop first-in-class gene therapy for cystic fibrosis
- Bayer Cares Foundation promotes sustainable growth by supporting social impact pioneers with grants totaling EUR 1 million
- Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island
- Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
Research & Development
- The medicine of the future against infection and inflammation?
- Compounds in 'monster' radish could help tame cardiovascular disease
- Taking a pill can effectively treat brutal lung disease
- Differences in immune responses due to age, sex, and genetics
- Mushrooms of the Far East hold promise for the anti-cancer therapy
- Innovative technique converts white fat to brown fat
- Researchers design a nano-carrier to release drugs into damaged cells
Conferences & Events
- Lyophilization USA Conference 2018
- SMi presents the 13th annual industry leading conference: Cold Chain Distribution
- Orphan Drugs and Rare Diseases Conference 2018
- Immuno-Oncology Conference 2018
- Ophthalmic Drugs Conference 2018
- SMi presents the launch of Cell & Gene Therapy 2018
- SMi presents the 9th Conference on Biosimilars & Biobetters
Regulatory Affairs
- FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
- FDA approves treatment for two rare types of non-Hodgkin lymphoma
- FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
- FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
- FDA warns of imposters sending consumers fake warning letters